Johnson & Johnson said this week it would pay $5.5 billion to resolve roughly 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer, ending more than a decade of litigation over one of the company's signature products. The healthcare giant will pay up to $3 billion in 2027, with the remainder following in 2028, once the agreement is accepted by 95 percent of claimants, according to court filings and company statements.
The settlement follows a legal defeat that few saw coming. Earlier this month, a federal judge in New Jersey cast doubt on whether individual plaintiffs could show that talc specifically caused their cancer, rather than one of the many other risk factors associated with the disease, a standard the company had struggled for years to hold plaintiffs to at trial. That ruling arrived more than a year after J&J had declared it would rather fight than settle. The company had already tried, and failed three times, to offload the liability into a subsidiary through a bankruptcy filing, a maneuver known as the "Texas two-step" that bankruptcy judges repeatedly found improper. When that route closed for good in the spring of 2025, J&J returned to individual trials instead, winning most of the cases that went before a jury. This month's ruling appears to have changed the calculus enough to bring both sides back to the negotiating table.
For insurers, the case has functioned for years as shorthand in a broader argument about verdicts and litigation costs. J&J itself has largely operated outside that market: the company stopped purchasing new product liability coverage in 2005 and now relies on self-insurance, including through its own captive, Middlesex Assurance. A separate coverage dispute in New Jersey state court, Atlanta International Insurance Co. v. Johnson & Johnson, has pitted the company against legacy carriers on policies written before that cutoff, among them Travelers, Chubb, Allstate, Everest Re, TIG, North River and Wausau, and is expected to continue regardless of Monday's settlement.
That dynamic mirrors a wider shift in American casualty insurance. Umbrella and excess liability rates rose 8.2 percent in the first quarter of 2026, the highest reading in four quarters, as nuclear verdicts and social inflation continued to drive claims severity even as most other commercial lines softened. Nuclear verdicts, jury awards exceeding $10 million, reached a combined $31.3 billion in 2024, more than double the prior year, with product liability among the categories most affected.
Talc will not disappear from that conversation. The settlement covers only existing claims, not future ones, and it leaves untouched a separate case in London, where J&J's former consumer unit, Kenvue, is defending what has been described as the largest product liability lawsuit in British history. For American insurers watching the domestic litigation environment, the more immediate lesson may be one J&J has already drawn: when coverage becomes expensive or hard to find, the largest companies increasingly choose to carry the risk themselves.
